News

Japan's Cabinet Office approves 330 billion JPY package targeting bioclusters, rare disease trials, cell/gene therapy manufacturing, and biosimilars.

All 16 pharmaceutical companies that signed pricing deals with the Trump administration have increased list prices on multiple drugs in January 2026, highlighting tensions in US drug pricing negotiations.[2]

SCIEX announces the localization of its advanced XR QTOF and ZenoTOF analytical systems in China, enhancing access to cutting-edge life science technologies for Asian pharmaceutical R&D and manufacturing.

The newly agreed India-EU Free Trade Agreement eliminates tariffs on pharmaceuticals, enhancing supply chain security and opening Europe's $572.3 billion market to Indian B2B partners in manufacturing, APIs, and contract services.

Atradius forecasts robust 6.6% growth in Chinese pharmaceuticals production for 2026, fueled by biopharma innovations, R&D investments, and policy support amid Asia's leading regional expansion.

The European Parliament has adopted key proposals under the Critical Medicines Act to enhance EU pharmaceutical supply resilience, prioritize local production, and address shortages of essential drugs like antibiotics and insulin.

The EU Parliament has agreed on clear priorities for negotiations on the Critical Medicines Act, emphasizing investments in pharmaceutical manufacturing capacity to strengthen Europe's strategic autonomy in critical drug production.

Hengrui Pharma's stock surged 36% in 2025 driven by its transition from generic drugs to innovative therapies, securing over $700 million in upfront payments from Merck and GSK partnerships.

Primera Professional Pharmacy, a full-service pharmacy specializing in pharmaceutical compounding, announces the availability of the Demovectin Kit, a topical prescription ointment kit designed for lids and lashes and dispensed

The European Parliament has adopted key proposals under the Critical Medicines Act to enhance medicine availability, reduce external dependencies, and strengthen the EU's pharmaceutical industry competitiveness.